{"prompt": "['56.', 'Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of', 'tacrolimus ointment after first and repeated application to children with atopic', 'dermatitis. J Invest Dermatol. Apr 2005;124(4):695-699.', '57.', 'Albinana V, Sanz-Rodriguez F, Recio-Poveda L, Bernabeu C, Botella LM.', 'Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1', 'expression and modulates transforming growth factor-beta1 signaling in endothelial', 'cells. Molecular pharmacology. May 2011;79(5):833-843', '58.', 'Dupuis-Girod S, Chesnais AL, Ginon I, et al. Long-term outcome of patients with', 'hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic', 'liver transplantation: a single-center study. Liver Transpl. Mar 10;16(3):340-347', '59.', 'Skaro Al, Marotta PJ, McAlister VC. Regression of cutaneous and gastrointestinal', 'telangiectasia with sirolimus and aspirin in a patient with hereditary hemorrhagic', 'telangiectasia. Ann Intern Med. Feb 7 2006;144(3):226-227.', '60.', 'Salloum R, Fox CE, Alvarez-Allende CR, et al. Response of Blue Rubber Bleb Nevus', 'Syndrome to Sirolimus Treatment. Pediatric blood & cancer. Jun 8 2016.', '61.', 'Yesil S, Tanyildiz HG, Bozkurt C, Cakmakci E, Sahin G. Single-center experience with', 'sirolimus therapy for vascular malformations. Pediatric hematology and oncology. Apr', '2016;33(3):219-225.', '62.', 'Park JH, Joo CK, Chung SK. Comparative study of tacrolimus and bevacizumab on', 'corneal neovascularization in rabbits. Cornea. Apr 2015;34(4):449-455.', '63.', 'Dupuis-Girod S, Ambrun A, Decullier E, et al. Effect of Bevacizumab Nasal Spray on', 'Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical', 'Trial. JAMA : the journal of the American Medical Association. Sep 6 2016;316(9):934-', '942.', '64.', 'Moiseev IS, Burmina EA, Muslimov AR, et al. Pharmacokinetic comparison of', 'cyclosporin A and tacrolimus in graft-versus-host disease prophylaxis. Ann Hematol.', 'Mar 25 2017.', '65.', 'Dupuis-Girod S, Ambrun A, Decullier E, et al. ELLIPSE Study: A Phase 1 study', 'evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in', 'hereditary hemorrhagic telangiectasia. mAbs. Jan 30 2014;6(3).', 'Page 60 of 64']['15 Appendices', '15.1 Appendix 1: Nosebleed monitoring sheet', 'RENDU-OSLER : FICHE DE SURVEILLANCE DES EPISTAXIS', 'Nom :', 'Pr\u00e9nom :', 'N\u00e9(e) le :', 'ANNEE 20', 'Inscrire dans la colonne correspondant au jour du mois, la dur\u00e9e en minutes de chaque \u00e9pistaxis.', 'MOIS :', 'Jour', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', '26', '27', '28', '29', '30', '31', 'Episode 1', 'Episode 2', 'Episode 3', 'Episode 4', 'Episode 5', 'Episode 6', 'Episode 7', 'Episode 8', 'Total', 'ADMIISTRATTON DE LA POMMADE PROTOPIC OU PLACEBO.', 'FAIRE UNE CROIX TOUSI LES JOURS POUR CHAQUE ADMINISTRATION', 'Jour', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', '26', '27', '28', '29', '30', '31', 'Matin', 'Soir', 'Jour', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', '26', '27', '28', '29', '30', '31', 'Transfusion', 'Nb CGR', 'Injection Fer', 'IV (mg)', 'Hemoglobine', \"Noter la liste des \u00e9v\u00e8nements que vous jugez importants survenus pendant cette p\u00e9riode, la date de d\u00e9but et de fin, la prise d'autres\", 'traitements :', 'Date :', 'Commentaire :', 'Page 61 of 64']\n\n###\n\n", "completion": "END"}